Neuropeptides and diabetic retinopathy
نویسندگان
چکیده
منابع مشابه
Neuropeptides and diabetic retinopathy.
Diabetic retinopathy, a common complication of diabetes, develops in 75% of patients with type 1 and 50% of patients with type 2 diabetes, progressing to legal blindness in about 5%. In the recent years, considerable efforts have been put into finding treatments for this condition. It has been discovered that peptidergic mechanisms (neuropeptides and their analogues, activating a diverse array ...
متن کاملAssociation between diabetic retinopathy and hemoglobin level
Background: Anemia may be considered to be an independent risk factor for the development of diabetic retinopathy (DR) in patients with renal failure. The purpose of this study was to investigate the association between blood hemoglobin level and retinopathy in diabetic patients with normal renal function tests.Methods: From 2009 to 2011, 1100 diabetic patients underwent retinal examination. Am...
متن کاملDiabetic retinopathy and diabetic neuropathy.
Perspectives on the News commentaries are now part of a new, free monthly CME activity. The Mount Sinai School of Medicine, New York, New York, is designating this activity for 2.0 AMA PRA Category 1 credits. If you wish to participate, review this article and visit www.diabetes.procampus.net to complete a posttest and receive a certificate. The Mount Sinai School of Medicine is accredited by t...
متن کاملCataract and diabetic retinopathy
patient with diabetes, you should remember that cataract surgery may make diabetic retinopathy worse. Eyes with mild to moderate non-proliferative diabetic retinopathy at the time of surgery are considered less at risk. Those with severe non-proliferative and proliferative diabetic retinopathy have a higher risk of progressive disease.1 Clinically significant macular oedema (CSMO) present at th...
متن کاملDiabetic Retinopathy and Hypertension
Diabetes is a systemic metabolic syndrome, in which high levels of blood glucose may be due to either a deficiency of insulin production (type I or insulin-dependent diabetes), or to a peripheral resistance to insulin action (type II or non-insulindependent diabetes). The resulting hyperglycemia leads to the activation of a series of events, such as the polyol pathway, the non-enzymatic glycosy...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Clinical Pharmacology
سال: 2013
ISSN: 0306-5251
DOI: 10.1111/bcp.12003